DomusVi completed a major capital reorganization, described as a "jumbo-LBO". This transaction allowed founder Yves Journel to increase his ownership from 30% to 49%, while ICG remains a key controlling partner. The group's management team also participated in the round, investing approximately €50 million for a 2% stake. The deal was financed through a robust structure including €1.6 billion in portable senior debt (representing 6.3x EBITDA) and a €400 million PIK (Payment-in-Kind) line provided by ICG. The strategic rationale is to fund a "European conquest" phase, aiming to double the group's revenue to €3.4 billion by 2025. This growth will be driven by massive external acquisitions in Germany, Italy, Belgium, and Portugal, further consolidating DomusVi's position as a dominant European healthcare provider.

DomusVi entered into exclusive negotiations to acquire 100% of the capital of Residalya, in a move designed to significantly densify its territorial coverage within France. The transaction allowed DomusVi to absorb 35 additional facilities and roughly 2,630 beds, bringing its total capacity to over 17,000 beds and narrowing the gap with its primary market competitors. This strategic build-up was motivated by the need to reach a critical industrial scale, merging Residalya’s localized expertise and specialized assets—including the ownership of twelve of its residences—into DomusVi’s global operational platform.

ICG and founder Yves Journel have entered into exclusive negotiations to acquire the majority stake in DomusVi from PAI Partners. The transaction, valuing the group at €2.3 billion, follows a preemptive bid by ICG that successfully bypassed a formal auction process involving major international investors and sovereign funds. This deal marks a significant change in scale for the group, which was valued at less than €650 million in 2014. The acquisition is structured to maintain the existing high-yield bond financing, as the continued presence of ICG and the founder in the capital prevents the activation of change-of-control repayment clauses. The strategic rationale centers on pursuing the international expansion of the group, particularly in markets like Spain, where the recent integration of SARquavitae has already propelled the company to a leadership position. The partnership intends to bridge the gap with major competitors such as Orpea and Korian-Medica by leveraging DomusVi's strong expertise in specialized care and home services.

DomusVi has successfully acquired its Spanish competitor SARquavitae, previously held by a consortium of investment funds including Palamon Capital Partners and G Square Capital. This transformative build-up operation allows the group to become the number one player in the Spanish elderly care market. The strategic rationale centers on geographic diversification, as the target’s strong footprint in Catalonia and Madrid perfectly complements the acquirer’s existing position in Galicia. The integration adds 88 facilities and 11,000 beds to the group’s portfolio, bringing total pro forma revenues to approximately €1.2 billion. This acquisition marks a significant milestone in the group’s international expansion strategy, following the previous year’s integration of another Spanish operator, thereby solidifying its leadership position in Southern Europe.